These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 13855275)

  • 21. Some biological features of Proteus bacilli. 2. Haemolytic activities of Proteus mirabilis and Proteus vulgaris strains.
    Kotelko K; Kaca W; Rózalski A; Deka M
    Acta Microbiol Pol; 1983; 32(4):345-51. PubMed ID: 6202102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ANTIBIOTIC THERAPY IN ESTABLISHED CHRONIC EXPERIMENTAL PROTEUS MIRABILIS PYELONEPHRITIS.
    HUNTER BW; SOUDA LL; SANFORD JP
    Antimicrob Agents Chemother (Bethesda); 1963; 161():608-12. PubMed ID: 14274971
    [No Abstract]   [Full Text] [Related]  

  • 23. [Conformational analysis of 5-substituted uracil].
    Stepan'ian SG; Radchenko ED; Sheina GG; Vlagoĭ IuP
    Biofizika; 1989; 34(5):753-7. PubMed ID: 2611271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of bacterial metabolism in transformation of non-mutagenic compounds into mutagens. II. Participation of bacteria producing urease in degradation of pesticides--urea derivatives].
    Szarapińska-Kwaszewska J; Mikucki J
    Med Dosw Mikrobiol; 1992; 44(1-2):35-40. PubMed ID: 1297032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigations on the mutagenic activity of STS 557.
    Schöneich J; Becker K; Braun R
    Exp Clin Endocrinol; 1983 Feb; 81(2):210-6. PubMed ID: 6343101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutagenic mechanism of the A-T to G-C transition induced by 5-bromouracil: an ab Initio Study.
    Hu X; Li H; Ding J; Han S;
    Biochemistry; 2004 Jun; 43(21):6361-9. PubMed ID: 15157069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization and serological classification of O-specific polysaccharide of Proteus mirabilisTG 276-90 from Proteus serogroup O34.
    Kołodziejska K; Siwińska M; Zych K; Rózalski A; Sidorczyk Z
    Arch Immunol Ther Exp (Warsz); 2006; 54(3):223-6. PubMed ID: 16736109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-Bromouracil: a new inhibitor of glucose-6-phosphate dehydrogenase.
    HOCHSTER RM
    Biochem Biophys Res Commun; 1961 Nov; 6():289-92. PubMed ID: 13907914
    [No Abstract]   [Full Text] [Related]  

  • 29. Changes in metabolic activity of Proteus mirabilis during swarming.
    Armitage JP
    J Gen Microbiol; 1981 Aug; 125(2):445-50. PubMed ID: 7033472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Proteus mirabilis MR/P fimbriae and flagella in adhesion, cytotoxicity and genotoxicity induction in T24 and Vero cells.
    Scavone P; Villar S; Umpiérrez A; Zunino P
    Pathog Dis; 2015 Jun; 73(4):. PubMed ID: 25724892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunochemical studies on the O-antigens of Proteus mirabilis O23 and Proteus vulgaris O23.
    Rózalski A; Perepelov AV; Bartodziejska B; Senchenkova SN; Babicka D; Kaca W; Knirel YA
    Arch Immunol Ther Exp (Warsz); 2003; 51(1):69-74. PubMed ID: 12691306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Serologic studies of cross reactions between strains of Proteus mirabilis OXK (prO 10/52) and Proteus mirabilis S1959].
    Swierzko AS; Cedzyński M; Ziółkowski A; Kaca W
    Postepy Hig Med Dosw; 1996; 50(5):507-9. PubMed ID: 9072766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on variation in virulence of poliomyelitis virus. IV. The effect of 5-bromouracil and stable cell lines.
    LI CP
    J Immunol; 1959 Nov; 83():511-6. PubMed ID: 14416623
    [No Abstract]   [Full Text] [Related]  

  • 34. Transforming activity of deoxyribonucleic acid labelled with 5-bromouracil.
    SZYBALSKI W; OPARA-KUBINSKA Z; LORKIEWICZ Z; EPHRATI-ELIZUR E; ZAMENHOF S
    Nature; 1960 Nov; 188():743-5. PubMed ID: 13774707
    [No Abstract]   [Full Text] [Related]  

  • 35. Incorporation of 5-bromouracil into transforming principle of Bacillus subtilis and its biological effects.
    EPHRATI-ELIZUR E; ZAMENHOF S
    Nature; 1959 Aug; 184(Suppl 7)():472-3. PubMed ID: 13820463
    [No Abstract]   [Full Text] [Related]  

  • 36. Antimicrobial activity Study of triclosan-loaded WBPU on Proteus mirabilis in vitro.
    Tian Y; Jian Z; Wang J; He W; Liu Q; Wang K; Li H; Tan H
    Int Urol Nephrol; 2017 Apr; 49(4):563-571. PubMed ID: 28150092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteus mirabilis RMS 203 as a new representative of the O13 Proteus serogroup.
    Palusiak A; Siwińska M; Zabłotni A
    Acta Biochim Pol; 2015; 62(4):691-5. PubMed ID: 26645323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure of the O-polysaccharide of Proteus mirabilis OC (CCUG 10702) from a new proposed Proteus serogroup O75.
    Zabłotni A; Perepelov AV; Knirel YA; Sidorczyk Z
    Carbohydr Res; 2005 Aug; 340(11):1908-13. PubMed ID: 15979596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Phage resistance of stabile L-forms of Proteus mirabilis].
    TAUBENECK U
    Z Naturforsch B; 1961 Dec; 16B():849-50. PubMed ID: 14039668
    [No Abstract]   [Full Text] [Related]  

  • 40. Mannose-resistant Proteus-like and P. mirabilis fimbriae have specific and additive roles in P. mirabilis urinary tract infections.
    Zunino P; Sosa V; Schlapp G; Allen AG; Preston A; Maskell DJ
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):125-33. PubMed ID: 17854474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.